Genetic disorder
Medical condition
Bosma arhinia microphthalmia ayndrome' (BAMS), Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome, or just Bosma syndrome is a rare genetic disorder characterized by nasal and ocular abnormalities, often accompanied by endocrine dysfunction.
Presentation.
The typical indicator of BAMS is arrhinia, characterized by the complete absence of an external nose or, in some cases, a severely underdeveloped (hypoplastic) nose. This is often accompanied by the absence of olfactory bulb, leading to impaired smell (hyposmia or anosmia) and taste (ageusia). Patients typically exhibit microphthalmia (abnormally small eyeballs) or anophthalmia (absence of eyeballs), resulting in severe vision impairment or blindness. Additional eye abnormalities may include colobomas, cataracts, and nasolacrimal duct obstruction. Common craniofacial abnormalities include a high-arched or cleft palate, absence of paranasal sinuses, choanal atresia, and a hypoplastic maxilla. Some patients may also present with external ear abnormalities. BAMS is associated with hypogonadotropic hypogonadism, leading to absent or delayed puberty and sexual development. This can manifest as underdeveloped genitals in males and lack of breast development or menstruation in females. Despite the severe craniofacial abnormalities, patients with BAMS typically have normal cognition and intellectual abilities.
Genetics.
Bosma arhinia microphthalmia syndrome is primarily caused by mutations in the SMCHD1 gene, which encodes a protein involved in gene silencing during embryonic development and is particularly important to the development of the head and facial features. These mutations are typically de novo and occur in the N-terminal GHKL-type ATPase domain, suggesting a gain-of-function effect that disrupts normal nasal and ocular development. BAMS follows an autosomal dominant inheritance pattern, meaning a single mutated copy of the SMCHD1 gene can cause the disorder. While SMCHD1 is the primary gene implicated, other unknown genetic factors may also contribute to the condition's severity.
Pathophysiology.
The SMCHD1 gene plays a critical role in craniofacial development by regulating chromatin structure and gene expression during embryogenesis. Disruption in these processes due to SMCHD1 mutations can lead to the developmental anomalies observed in BAMS.
Diagnosis.
Bosma arhinia microphthalmia syndrome is typically diagnosed at birth due to its distinct facial features, such as the absence of the nose and small or absent eyes. The initial diagnosis is primarily based on a thorough physical examination. However, genetic testing is needed to confirm the diagnosis by identifying mutations in the SMCHD1 gene. The SMCHD1 gene is analyzed using techniques such as next-generation sequencing to detect pathogenic variants that are characteristic of BAMS. Such analyses are needed to distinguish BAMS from other syndromes that present with similar craniofacial abnormalities, such as CHARGE syndrome or Treacher Collins syndrome. Due to potential endocrine dysfunctions associated with BAMS, hormonal evaluations may be conducted to assess for hypogonadotropic hypogonadism, which is common in affected individuals.
Treatment.
Treatment is primarily symptomatic and focuses on addressing the needs of each individual. Given the complexity and rarity of the syndrome, a multidisciplinary approach is often required, involving specialists such as pediatricians, endocrinologists, ophthalmologists, and craniofacial surgeons. Surgical reconstruction can be considered to improve both function and appearance of the nose. This may involve multiple staged surgeries to create a nasal structure that allows for normal breathing and enhances facial aesthetics. Advances in technology, such as 3D printing, have enhanced the ability to create custom nasal implants, improving cosmetic outcomes. For individuals with microphthalmia or anophthalmia, ocular prosthesis can be used to improve cosmetic appearance. In cases where some vision is present, ophthalmologists may provide interventions to maximize visual function.
Individuals with BAMS experience hypogonadotropic hypogonadism due to disrupted gonadotropin-releasing hormone (GnRH) neurons. Hormone therapy can help manage this condition by supplementing deficient hormones, thereby supporting normal pubertal development and fertility when appropriate. Given the visible nature of craniofacial differences and potential social challenges, psychological support and counseling are often recommended for patients and their families. Genetic counseling is also recommended to provide information about the hereditary aspects of BAMS. Regular follow-up care is essential to monitor growth, development, and any emerging complications. This includes managing associated comorbidities such as vitamin D deficiency, which can lead to osteoporosis if untreated.
Epidemiology.
Bosma arhinia microphthalmia syndrome is an extremely rare genetic disorder, with fewer than 100 reported cases worldwide. Due to its rarity, precise epidemiological data, including incidence and prevalence rates, are not well established. The condition appears to affect both males and females equally, although specific gender-based prevalence data are lacking. BAMS has been documented in various populations globally, but the distribution of cases does not suggest any particular ethnic or geographic predisposition. The rarity of the syndrome means that it often goes unreported in many regions, contributing to the difficulty in gathering comprehensive epidemiological data.
References.
 ;templatestyles src="Reflist/styles.css" / ;